Alzheimer's Disease with Mild to Moderate Cognitive Impairment: What to Do When Cholinesterase Inhibitor Therapy Fails

This protocol addresses the next clinical step for patients with a confirmed clinical diagnosis of Alzheimer's disease and mild to moderate cognitive impairment in whom the initial pharmacological approach did not produce the expected cognitive benefit within the anticipated timeframe.

Clinical Scenario

The patient has a clinical diagnosis of Alzheimer's disease with mild to moderate cognitive impairment. Cholinesterase inhibitors — such as donepezil and galantamine — are established first-line options for this presentation and carry evidence of moderate effect sizes at this stage of the disease.

Escalation Trigger — First-Line Treatment Did Not Succeed

The prior treatment consisted of a cholinesterase inhibitor (donepezil, galantamine, or rivastigmine), titrated gradually, with possible addition of cognitive stimulation. Escalation to this protocol is indicated when the primary target was not met: improved cognitive function was not appreciable within 12 weeks of initiating that therapy. This unmet goal is the clinical basis for advancing to the next line.

Next-Step Approach

When the initial cholinesterase inhibitor alone is insufficient, the protocol describes a combination pharmacotherapy approach — adding a second agent from a different class — indicated for cases where the disease has progressed or the monotherapy target was not reached. The full regimen, criteria, and sequencing are contained in the structured protocol.

Full regimen and selection criteria available below ↓

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/S0140-6736(25)01329-7

Meta-analyses indicate that galantamine (≥24 mg) and donepezil (10 mg) are most effective for mild to moderate Alzheimer's disease, with moderate effect sizes (galantamine 0·5 and donepezil 0·4).

Combining memantine (20 mg) with donepezil (10 mg) shows the largest benefit (effect size 0·76) and is recommended for moderate to severe cases.

View source ↗